These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19586872)

  • 1. [In vivo delivery of siRNA].
    Shi ML; Zhao ZH; Wang Y; Chen HP
    Yi Chuan; 2009 Jul; 31(7):683-8. PubMed ID: 19586872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery vehicles for small interfering RNA in vivo.
    de Fougerolles AR
    Hum Gene Ther; 2008 Feb; 19(2):125-32. PubMed ID: 18257677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipidic systems for in vivo siRNA delivery.
    Wu SY; McMillan NA
    AAPS J; 2009 Dec; 11(4):639-52. PubMed ID: 19757082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S; Zhao B; Jiang H; Wang B; Ma B
    J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research progress on the development of the strategies for siRNAs delivery in vivo].
    Tang D; Mao A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes.
    Hossain S; Stanislaus A; Chua MJ; Tada S; Tagawa Y; Chowdhury EH; Akaike T
    J Control Release; 2010 Oct; 147(1):101-8. PubMed ID: 20620182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: a promising approach in liver-specific RNAi delivery.
    Sajeesh S; Lee TY; Kim JK; Son DS; Hong SW; Kim S; Yun WS; Kim S; Chang C; Li C; Lee DK
    J Control Release; 2014 Dec; 196():28-36. PubMed ID: 25251899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress in transdermal delivery for small interfering RNA].
    Chen Y; Xu N; Hu Z
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):622-631. PubMed ID: 32347057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1-specific RNA interference.
    Boden D; Pusch O; Ramratnam B
    Curr Opin Mol Ther; 2004 Aug; 6(4):373-80. PubMed ID: 15468596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
    Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
    Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
    Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
    Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.
    Scherman D; Rousseau A; Bigey P; Escriou V
    Gene Ther; 2017 Mar; 24(3):151-156. PubMed ID: 28121307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical and structural modifications of RNAi therapeutics.
    Ku SH; Jo SD; Lee YK; Kim K; Kim SH
    Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA and RNAi optimization.
    Alagia A; Eritja R
    Wiley Interdiscip Rev RNA; 2016 May; 7(3):316-29. PubMed ID: 26840434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.